PhaseRx, Inc.
PZRXQ · OTC
12/31/2016 | 12/31/2015 | 12/31/2014 | |
|---|---|---|---|
| Revenue | $0 | $0 | $1 |
| % Growth | -100% | -68.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $1 |
| % Margin | – | 100% | 100% |
| R&D Expenses | $7 | $5 | $5 |
| G&A Expenses | $4 | $1 | $2 |
| SG&A Expenses | $12 | $1 | $2 |
| Sales & Mktg Exp. | $8 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 |
| Operating Expenses | $18 | $6 | $7 |
| Operating Income | -$18 | -$6 | -$6 |
| % Margin | – | -1,548.5% | -465.9% |
| Other Income/Exp. Net | -$2 | -$2 | -$1 |
| Pre-Tax Income | -$20 | -$7 | -$7 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$20 | -$7 | -$7 |
| % Margin | – | -1,967.2% | -570.8% |
| EPS | -2.68 | -0.94 | -1.16 |
| % Growth | -185.1% | 19% | – |
| EPS Diluted | -2.68 | -0.94 | -1.16 |
| Weighted Avg Shares Out | 8 | 8 | 6 |
| Weighted Avg Shares Out Dil | 8 | 8 | 6 |
| Supplemental Information | – | – | – |
| Interest Income | $0 | $0 | $0 |
| Interest Expense | $2 | $2 | $1 |
| Depreciation & Amortization | $0 | $0 | $1 |
| EBITDA | -$18 | -$5 | -$5 |
| % Margin | – | -1,439.2% | -414.2% |